亚盛医药 AAPG 深 沪
等待开盘 01-31 09:30:00 美东时间
24.18
-0.820
-3.28%
华盛通- 最 高24.80
- 今 开24.80
- 成交量 9594股
- 最 低 24.18
- 昨 收 25.00
- 总市值 22.53亿
- 52周最高 48.45
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 17.09
- 委 比 -64.71%
- 总股本 9316.78万
- 历史最高 48.45
- 量 比 3.81
- 振 幅 2.48%
- 历史最低 17.00
- 每 手 1
- 风险率 8.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多创新药还能加仓？这场会定调2026
经济观察报 记者 张英 2026年1月16日，陈影从旧金山飞回上海，飞机上坐满了中国创新药企的创始人、高管、投资者，大部分人看上去心情不错，他们刚参加完全球规模...
01-24 18:05
亚盛医药：“全球创新”战略迈入新阶段丨JPM大会
（来源：抗体圈） 两大核心产品构建血液肿瘤治疗版图 亚盛医药两大核心产品——第三代BCR-ABL抑制剂奥雷巴替尼与Bcl-2抑制剂利沙托克拉在20...
01-15 18:27
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
Ascentage Pharma announced its 2025 milestones and 2026 global strategy, highlighting dual-engine growth from Olverembatinib and Lisaftoclax, IND clearance for APG-3288, and progress in multiple Phase III trials. The company aims to accelerate innovation and expand its portfolio to address unmet needs in cancer treatment.
01-15 01:25
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesd...
01-07 23:03
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
Ascentage Pharma's novel BTK-targeted protein degrader APG-3288 has received FDA IND clearance, enabling a global Phase I study in relapsed/refractory B-cell malignancies. Unlike conventional BTK inhibitors, APG-3288 degrades BTK, addressing resistance and offering a potential new therapeutic strategy. The study aims to assess safety, tolerability, PK, and efficacy, marking a major milestone for the company's innovative pipeline.
01-07 01:00
亚盛医药荣获“格隆汇金格奖·年度卓越生物医药企业”奖
格隆汇12月22日线上举办“科技赋能·资本破局”分享会。备受瞩目的卓越公司评选榜单隆重揭晓。其中，格隆汇“金格奖”年度卓越公司评选中，亚盛医药(06855.H...
2025-12-23 20:19
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference
Ascentage Pharma Group International Unsponsored ADR ( ($AAPG) ) has issued an ...
2025-12-17 21:58
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. PT in San Francisco. The company, focused on developing novel cancer therapies, has two approved products: Olverembatinib, a third-generation BCR-ABL1 inhibitor for chronic myeloid leukemia (CML) patients with T315I mutations, and Lisaftoclax, a Bcl-2 inhi...
2025-12-17 13:00
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
亚盛医药-B(06855)耐立克一线治疗Ph+ ALL的全球注册III期临床研究获美国FDA和欧洲EMA批准
亚盛医药-B(06855)发布公告，公司原创1类新药奥雷巴替尼(商品名：耐立克®)联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病(ALL)患者的全...
2025-12-05 08:03
